Cargando…
Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1
BACKGROUND: Lectin-like oxidized low-density-lipoprotein receptor 1 (Lox-1) is the receptor for oxidized low-density lipoprotein (oxLDL), a mediator in dyslipidemia. Toll-like receptor (TLR)-2 and − 4 are receptors of lipopolysaccharide (LPS) from Porphyromonas gingivalis, a major pathogen of chroni...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985062/ https://www.ncbi.nlm.nih.gov/pubmed/29859535 http://dx.doi.org/10.1186/s12944-018-0787-4 |
_version_ | 1783328696258527232 |
---|---|
author | Ohgi, Kimiko Kajiya, Hiroshi Goto-T, Kazuko Okamoto, Fujio Yoshinaga, Yasunori Okabe, Koji Sakagami, Ryuji |
author_facet | Ohgi, Kimiko Kajiya, Hiroshi Goto-T, Kazuko Okamoto, Fujio Yoshinaga, Yasunori Okabe, Koji Sakagami, Ryuji |
author_sort | Ohgi, Kimiko |
collection | PubMed |
description | BACKGROUND: Lectin-like oxidized low-density-lipoprotein receptor 1 (Lox-1) is the receptor for oxidized low-density lipoprotein (oxLDL), a mediator in dyslipidemia. Toll-like receptor (TLR)-2 and − 4 are receptors of lipopolysaccharide (LPS) from Porphyromonas gingivalis, a major pathogen of chronic periodontitis. Although some reports have demonstrated that periodontitis has an adverse effect on dyslipidemia, little is clear that the mechanism is explained the effects of dyslipidemia on osteoclastogenesis. We have hypothesized that osteoclast oxLDL has directly effect on osteoclasts (OCs), and therefore alveolar bone loss on periodontitis may be increased by dyslipidemia. The present study aimed to elucidate the effect of Lox-1 on osteoclastogenesis associated with TLRs in vitro. METHODS: Mouse bone marrow cells (BMCs) were stimulated with macrophage colony-stimulating factor into bone marrow macrophages (BMMs). The cells were also stimulated with synthetic ligands for TLR2 (Pam3CSK4) or TLR4 (Lipid A), with or without receptor activator of nuclear factor kappa-B ligand (RANKL), and assessed for osteoclastogenesis by tartrate-resistant acid phosphatase (TRAP) staining, immunostaining, western blotting, flow activated cell sorting (FACS) analysis, real-time polymerase chain reaction (PCR), and reverse transcription PCR. RESULTS: Lox-1 expression was significantly upregulated by Pam3CSK4 and Lipid A in BMCs (p < 0.05), but not in BMMs. FACS analysis identified that Pam3CSK4 upregulated RANK and Lox-1 expression in BMCs. TRAP-positive cells were not increased by stimulation with Pam3CSK4 alone, but were increased by stimulation with combination combined Pam3CSK and oxLDL. Expression of both Lox-1 and myeloid differentiation factor 88 (MyD88), an essential adaptor protein in the TLR signaling pathway, were suppressed by inhibitors of TLR2, TLR4 and mitogen-activated protein kinase (MAPK). CONCLUSIONS: This study supports that osteoclastogenesis is promoted under the coexistence of oxLDL by TLR2-induced upregulation of Lox-1 in BMCs. This indicates that periodontitis could worsen with progression of dyslipidemia. |
format | Online Article Text |
id | pubmed-5985062 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59850622018-06-07 Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1 Ohgi, Kimiko Kajiya, Hiroshi Goto-T, Kazuko Okamoto, Fujio Yoshinaga, Yasunori Okabe, Koji Sakagami, Ryuji Lipids Health Dis Research BACKGROUND: Lectin-like oxidized low-density-lipoprotein receptor 1 (Lox-1) is the receptor for oxidized low-density lipoprotein (oxLDL), a mediator in dyslipidemia. Toll-like receptor (TLR)-2 and − 4 are receptors of lipopolysaccharide (LPS) from Porphyromonas gingivalis, a major pathogen of chronic periodontitis. Although some reports have demonstrated that periodontitis has an adverse effect on dyslipidemia, little is clear that the mechanism is explained the effects of dyslipidemia on osteoclastogenesis. We have hypothesized that osteoclast oxLDL has directly effect on osteoclasts (OCs), and therefore alveolar bone loss on periodontitis may be increased by dyslipidemia. The present study aimed to elucidate the effect of Lox-1 on osteoclastogenesis associated with TLRs in vitro. METHODS: Mouse bone marrow cells (BMCs) were stimulated with macrophage colony-stimulating factor into bone marrow macrophages (BMMs). The cells were also stimulated with synthetic ligands for TLR2 (Pam3CSK4) or TLR4 (Lipid A), with or without receptor activator of nuclear factor kappa-B ligand (RANKL), and assessed for osteoclastogenesis by tartrate-resistant acid phosphatase (TRAP) staining, immunostaining, western blotting, flow activated cell sorting (FACS) analysis, real-time polymerase chain reaction (PCR), and reverse transcription PCR. RESULTS: Lox-1 expression was significantly upregulated by Pam3CSK4 and Lipid A in BMCs (p < 0.05), but not in BMMs. FACS analysis identified that Pam3CSK4 upregulated RANK and Lox-1 expression in BMCs. TRAP-positive cells were not increased by stimulation with Pam3CSK4 alone, but were increased by stimulation with combination combined Pam3CSK and oxLDL. Expression of both Lox-1 and myeloid differentiation factor 88 (MyD88), an essential adaptor protein in the TLR signaling pathway, were suppressed by inhibitors of TLR2, TLR4 and mitogen-activated protein kinase (MAPK). CONCLUSIONS: This study supports that osteoclastogenesis is promoted under the coexistence of oxLDL by TLR2-induced upregulation of Lox-1 in BMCs. This indicates that periodontitis could worsen with progression of dyslipidemia. BioMed Central 2018-06-02 /pmc/articles/PMC5985062/ /pubmed/29859535 http://dx.doi.org/10.1186/s12944-018-0787-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Ohgi, Kimiko Kajiya, Hiroshi Goto-T, Kazuko Okamoto, Fujio Yoshinaga, Yasunori Okabe, Koji Sakagami, Ryuji Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1 |
title | Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1 |
title_full | Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1 |
title_fullStr | Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1 |
title_full_unstemmed | Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1 |
title_short | Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1 |
title_sort | toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985062/ https://www.ncbi.nlm.nih.gov/pubmed/29859535 http://dx.doi.org/10.1186/s12944-018-0787-4 |
work_keys_str_mv | AT ohgikimiko tolllikereceptor2activationprimesandupregulatesosteoclastogenesisvialox1 AT kajiyahiroshi tolllikereceptor2activationprimesandupregulatesosteoclastogenesisvialox1 AT gototkazuko tolllikereceptor2activationprimesandupregulatesosteoclastogenesisvialox1 AT okamotofujio tolllikereceptor2activationprimesandupregulatesosteoclastogenesisvialox1 AT yoshinagayasunori tolllikereceptor2activationprimesandupregulatesosteoclastogenesisvialox1 AT okabekoji tolllikereceptor2activationprimesandupregulatesosteoclastogenesisvialox1 AT sakagamiryuji tolllikereceptor2activationprimesandupregulatesosteoclastogenesisvialox1 |